PacBio® RS Compatible Products Now Available Through Pacific Biosciences Partner Program

MENLO PARK, Calif.–(BUSINESS WIRE)–

Pacific Biosciences of California, Inc. (NASDAQ:PACB), provider of

Single Molecule Real Time (SMRT^®) sequencing products, today

announced the first PacBio^® RS compatible products

available through its Partner Program. These solutions complement and

enhance key aspects of the PacBio RS sequencing workflow,

providing customers with integrated workflows from sample preparation to

analysis.

The PacBio RS is a revolutionary DNA sequencing system that

reveals new biological insights by incorporating novel, single molecule

sequencing techniques, advanced analytics, and long read lengths. The

following products are now fully compatible with the PacBio RS

data and workflow to provide whole product solutions for de novo

whole genome assembly and targeted sequencing.

For shearing of genomic DNA:

• g-TUBE™ from Covaris, a single-use consumable that enables scientists

  to shear genomic DNA into selected fragment sizes ranging from 6kb to

  20kb. Up to 24 samples can be processed in several minutes and the

  fragments can go directly into the SMRTbell™ template preparation

  process.

For target enrichment:

• Access Array™ System from Fluidigm, a target enrichment platform

  designed for resequencing selected regions of a genome. When combined

  with PacBio barcodes, the system can generate 48 amplicons for each of

  48 samples and go directly into the SMRTbell template preparation

  process.

• SureSelect™ Target Enrichment System from Agilent Technologies

  improves the cost and process efficiency of the sequencing workflow.

  The system has demonstrated the ability to capture targeted fragments

  up to 2kb in length that are ready for SMRTbell template preparation.

For informatics:

• BG7 Bacterial Genome Annotation Service from Era7 Bioinformatics for

  gene and RNA prediction from PacBio de novo assemblies.

• Exemplar LIMS from Sapio Sciences has pre-loaded PacBio protocols and

  offers a workflow-driven architecture and plugin framework for

  automating sample preparation through sequencing and analysis.

• The GenoLogics LIMS provides preconfigured workflows for many genomics

  platforms including the PacBio RS. It provides the end-to-end

  sample traceability that genomics labs require to ensure the quality

  and integrity of their results.

• CLC Genomics Workbench and CLC Genomics Server from CLC bio can

  take alignments from the PacBio RS to call SNPs and perform

  tertiary analysis, giving scientists an easy way to do functional

  classification and filtering of SNPs and other genomic variations

  using multiple data sources.

• Partek^® Flow™, with an intuitive user interface designed

  with the biologist and informaticist in mind, provides increased

  quality control, powerful statistics for variant detection and copy

  number analysis, as well as dynamic visualizations for informative

  views of data and biomarker identification of aligned PacBio reads.

• SeqMan^® NGen^® from DNASTAR, Inc., sequence

  assembly software that can perform reference-based alignment of PacBio

  data and call SNPs quickly and accurately on a desktop computer.

  SeqMan NGen also easily integrates PacBio data with data from other

  sequencing platforms for integrated sequence assembly projects, if

  desired.

• SNP & Variation Suite 7 (SVS) from Golden Helix, an integrated

  collection of user-friendly, yet powerful tools for variant

  classification, bioinformatic filtering, functional annotation,

  visualization, and statistical analysis for quickly uncovering

  statistically significant genotype/phenotype associations or causal

  variants from PacBio variant calls.

For more information about these products, please visit the Pacific

Biosciences Partner Products website at www.pacb.com/partner_products.

The Wellcome Trust Sanger Institute is among the PacBio customers who

have experience using a product developed out of the Partner Program.

“We have been using the g-TUBES from Covaris to prepare libraries for

use on the PacBio RS,” said Paul Coupland, Project Manager,

PacBio Instrument Development Project at the Sanger Institute. “We found

that they speed up the library preparation step.”

Michael Glynn, Chief Commercial Officer for Pacific Biosciences,

commented: “We are delighted with the progress we’ve made working with

these companies since we launched our Partner Program. The products that

are resulting from these collaborations further support our customers to

perform key applications on the PacBio RS such as targeted

sequencing and de novo whole genome assembly, and advance our

goal of providing whole product solutions.”

Pacific Biosciences partners, customers and scientists will be

presenting data generated with the PacBio RS and some of these

co-developed solutions at this week’s Advances in Genome Biology &

Technology (AGBT) conference in Marco Island, Fla. For more information

please visit: www.pacb.com/agbt2012.

About Pacific Biosciences

Pacific Biosciences’ mission is to transform the way humankind acquires,

processes and interprets data from living systems through the design,

development and commercialization of innovative tools for biological

research. The company has developed a novel approach to studying the

synthesis and regulation of DNA, RNA and proteins. Combining recent

advances in nanofabrication, biochemistry, molecular biology, surface

chemistry and optics, Pacific Biosciences has created a powerful

technology platform called single molecule, real-time, or SMRT^®,

technology. SMRT technology enables real-time analysis of biomolecules

with single molecule resolution, which has the potential to transform

the understanding of biological systems by providing a window into these

systems that has not previously been open for scientific study.

For more information about Pacific Biosciences, please visit www.pacb.com.

You can also follow the company on Twitter: www.twitter.com/pacbio.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking

statements may contain words such as “believe,” “may,” “estimate,”

“anticipate,” “continue,” “intend,” “expect,” “plan,” the negative of

these terms, or other similar expressions, and include the assumptions

that underlie such statements. Such statements include, but are not

limited to, statements regarding the Company’s SMRT technology. These

statements are subject to known and unknown risks and uncertainties that

could cause actual results to differ materially from those expressed or

implied by such statements, including but not limited to risks discussed

from time to time in documents Pacific Biosciences of California, Inc.

has filed with the Securities and Exchange Commission, including the

risks identified under the section captioned “Risk Factors” in its most

recently filed Quarterly Report on Form 10-Q. All forward-looking

statements are based on estimates, projections and assumptions as of the

date hereof. Pacific Biosciences undertakes no obligation to update any

forward-looking statements.

Media:
For Pacific Biosciences:Nicole

Litchfield, 415-793-6468
nicole@bioscribe.com
Investors:
Pacific

Biosciences:Trevin Rard, 650-521-8450
ir@pacificbiosciences.com

Source: Pacific Biosciences of California, Inc.

News Provided by Acquire Media